Literature DB >> 12364471

Effects of hormone replacement therapy and hepatic lipase polymorphism on serum lipid profiles in postmenopausal Japanese women.

Yoshiaki Somekawa1, Hidenori Umeki, Kimiko Kobayashi, Sigeo Tomura, Takeshi Aso, Hideo Hamaguchi.   

Abstract

The purpose of this study was to evaluate the relationships among hepatic lipase (HL) polymorphism, serum lipids, lipoproteins, and remnant-like particle cholesterol (RLP-C) and to determine the effects of hormone replacement therapy (HRT). We assessed the HL polymorphism in 209 postmenopausal Japanese women. Levels of serum total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, triglycerides, apolipoprotein (Apo) AI, Apo B, Apo E, Apo CII, Apo CIII, and RLP-C were measured before and after 3 months of HRT. The frequency of each genotype was 32% for -514 C/C, 41% for C/T, and 27% for T/T. Subjects with the C/T and T/T genotypes had higher levels of HDL cholesterol and Apo AI than those with the C/C genotype. Those with the T/T genotype had higher levels of RLP-C than those with the C/C or C/T genotype. Serum total cholesterol, LDL cholesterol, Apo B, Apo E, and Apo CII were decreased, and HDL cholesterol and Apo AI were increased significantly in all genotypes after 3 months of HRT. There were no differences in these changes with genotype. The HL polymorphism was associated with higher levels of HDL cholesterol, Apo AI, and RLP-C, and the HL gene variation may contribute to HL activity and affect serum lipoprotein metabolism. Effects of HRT on serum lipids, lipoproteins, and remnant lipoprotein metabolism were unaffected by the HL polymorphism.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364471     DOI: 10.1210/jc.2002-020245

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Positive association of the hepatic lipase gene polymorphism c.514C > T with estrogen replacement therapy response.

Authors:  Alvaro Pulchinelli; Ana Maria Massad Costa; Cristina V de Carvalho; Naiara Correa Nogueira de Souza; Mauro A Haidar; Adagmar Andriolo; Ismael D C Guerreiro da Silva
Journal:  Lipids Health Dis       Date:  2011-11-02       Impact factor: 3.876

2.  Association between hepatic lipase -514 C/T promoter polymorphism and myocardial infarction is modified by history of hypercholesterolemia and waist circumference.

Authors:  A Baylin; E Ruiz-Narvaez; M K Jensen; E Rimm; H Campos
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-08-19       Impact factor: 4.222

3.  Association of polymorphisms in genes involved in lipoprotein metabolism with plasma concentrations of remnant lipoproteins and HDL subpopulations before and after hormone therapy in postmenopausal women.

Authors:  Stefania Lamon-Fava; Bela F Asztalos; Timothy D Howard; David M Reboussin; Katalin V Horvath; Ernst J Schaefer; David M Herrington
Journal:  Clin Endocrinol (Oxf)       Date:  2009-05-29       Impact factor: 3.478

Review 4.  Pharmacogenetics of lipid diseases.

Authors:  Jose M Ordovas
Journal:  Hum Genomics       Date:  2004-01       Impact factor: 4.639

5.  Association between the Hepatic Lipase Promoter Region Polymorphism (-514 C/T) and the Presence and Severity of Premature Coronary Artery Disease.

Authors:  Hamidreza Goodarzynejad; Mohammadali Boroumand; Mehrdad Behmanesh; Shayan Ziaee; Arash Jalali; Leyla Pourgholi
Journal:  J Tehran Heart Cent       Date:  2017-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.